Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline

Core Viewpoint - Jacobio Pharma's subsidiary has entered into a significant agreement with Oceanpine Capital, acquiring 80% equity in Jacoray for RMB 200 million, which will enhance its focus on oncology innovation and support R&D efforts [1][2]. Group 1: Transaction Details - Oceanpine Capital will acquire an 80% equity interest in Jacoray for a total consideration of RMB 200 million, consisting of RMB 125 million upfront and RMB 75 million as a milestone payment [1]. - After the transaction, the equity distribution will be 10% for Beijing Jacobio, 80% for Oceanpine Capital, and 10% for an industry partner [1]. Group 2: Strategic Focus - The transaction aligns with Jacobio's strategic focus on developing innovative oncology therapies, particularly in the KRAS pathway and iADC [2]. - Proceeds from the transaction will primarily support the R&D, production, and commercialization of Jacobio's Pan-KRAS inhibitor and other oncology assets [2]. Group 3: Leadership Statements - Oceanpine Capital's CEO highlighted Jacobio's scientific strength and strategic focus in oncology innovation, expressing eagerness to partner for the globalization of China's biotech innovation [3]. - Jacobio's Chairman emphasized that this partnership strengthens their commitment to advancing next-generation cancer therapies [3]. Group 4: Company Overview - Jacobio Pharma is focused on breakthrough treatments, with R&D centers in Beijing, Shanghai, and Boston, and clinical trials conducted at over 180 sites in China and more than 30 in the USA [3]. - Oceanpine Capital, founded in 2018, manages assets exceeding RMB 25 billion and focuses on long-term value investing in advanced technology, green technology, and life sciences [4].